Testosterone nasal therapeutic - Acerus Pharmaceuticals
Latest Information Update: 28 Jun 2023
At a glance
- Originator Acerus Pharmaceuticals
- Class Anabolic steroids; Androstenols; Erectile dysfunction therapies; Hormonal replacements; Small molecules; Testosterone congeners
- Mechanism of Action Androgen receptor agonists; Growth stimulants; Hormone replacements; Testosterone congener stimulants; Testosterone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jun 2023 No recent reports of development identified for research development in Unspecified in Canada (Intranasal)
- 20 Jun 2019 Chemical structure information added
- 30 May 2019 Acerus Pharmaceuticals Corporation in-licenses aqueous-based, nasal delivery technology from University of Texas at Austin